Press releases
- RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome
- RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing
- RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome
- RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 164.07 |
Average volume | -- |
---|---|
Shares outstanding | 544.33m |
Free float | 307.55m |
P/E (TTM) | -- |
Market cap | 22.13bn HKD |
EPS (TTM) | -3.03 HKD |
Data delayed at least 20 minutes, as of Jan 27 2023.
More ▼